Missense mutation (I143T) in a Japanese patient with Canavan disease
Keiko Kobayashi
Department of Inherited Metabolic Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Seiichi Tsujino
Department of Inherited Metabolic Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan
Department of Inherited Metabolic Disease, National Institute of Neuroscience, NCNP, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo, 187 JapanSearch for more papers by this authorTakanori Ezoe
Department of Inherited Metabolic Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorHiroshi Hamaguchi
Department of Pediatrics, Tokyo Metropolitan Higashiyamato Medical Center for Handicapped, Tokyo, Japan
Search for more papers by this authorKenji Nihei
Department of Neurology, National Children's Hospital, Tokyo, Japan
Search for more papers by this authorNorio Sakuragawa
Department of Inherited Metabolic Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorKeiko Kobayashi
Department of Inherited Metabolic Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Seiichi Tsujino
Department of Inherited Metabolic Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan
Department of Inherited Metabolic Disease, National Institute of Neuroscience, NCNP, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo, 187 JapanSearch for more papers by this authorTakanori Ezoe
Department of Inherited Metabolic Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorHiroshi Hamaguchi
Department of Pediatrics, Tokyo Metropolitan Higashiyamato Medical Center for Handicapped, Tokyo, Japan
Search for more papers by this authorKenji Nihei
Department of Neurology, National Children's Hospital, Tokyo, Japan
Search for more papers by this authorNorio Sakuragawa
Department of Inherited Metabolic Disease, National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this author
References
- Hamaguchi H, Nihei K, Nakamoto N, Ezoe T, Naito H, Hara M, Yokota K, Inoue Y, Matsumoto I (1993) A case of Canavan disease: The first biochemically proven case in a Japanese girl. Brain Dev 15: 367–371.
- Kaul R, Gao GP, Balamurugan K, Matalon R (1993) Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 5: 118–123.
- Kaul R, Balamurugan K, Gao GP, Matalon R (1994a) Canavan disease: Genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Genomics 21: 364–370.
- Kaul R, Gao GP, Aloya M, Balamurugan K, Petrosky A, Michals K, Matalon R (1994b) Canavan disease: Mutations among Jewish and non-Jewish patients. Am J Hum Genet 55: 34–41.
- Kaul R, Gao GP, Michals K, Whelan DT, Levin S, Matalon R (1995) Novel cys152arg missense mutation in Arab patient with Canavan disease. Hum Mut 5: 269–271.
- Kaul R, Gao GP, Matalon R, Aloya M, Su Q, Jin M, Johnson AB, Schutgens RBH, Clarke JTR (1996) Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Am J Hum Genet 59: 95–102.
- Matalon R, Michals K, Sebesta D, Deanching M, Gashkoff P, Casanova J (1988) Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Caravan disease. Am J Med Genet 29: 463–471.
- Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF (1989) Analysis of any point mutation in DNA: The amplification refractory mutation system (ARMS). Nucleic Acid Res 17: 2503–2516.
- Shaag A, Anikster Y, Christensen E, Glustein JZ, Fois A, Michelakakis H, Nigro F, Pronicka E, Ribes A, Zabot MT, Elpeleg ON (1995) The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet 57: 572–580.
